Fluorine-18 labeling and biodistribution studies on peroxisome proliferator-activated receptor-γ ligands: potential positron emission tomography imaging agents

Nuclear Medicine and Biology

Volumn 36, Issue 2, 2009, Pages 147-153

  Lee, Byung Chul ^a   Dence, Carmen S ^b   Zhou, Haibing ^a   Parent, Ephraim E ^a   Welch, Michael J ^b   Katzenellenbogen, John A ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fluorine 18; Iodonium salt; Nucleophilic aromatic substitution; Peroxisome proliferator activated receptor ; PPAR ; Ullmann coupling

Indexed keywords

(2 BENZOYLPHENYLAMINO) 3 [4 [2 [2 (4 FLUOROPHENYL) 5 METHYLOXAZOL 4 YL]ETHOXY]PHENYL]PROPIONIC ACID F 18; 2 (4 FLUOROBENZOYL)PHENYLAMINO 3 [4 [2 (5 METHYL 2 PHENYLOXAZOL 4 YL)ETHOXY]PHENYL]PROPIONIC ACID; 2 IODO 4' FLUOROBENZOPHENONE F 18; BENZOPHENONE; CONTRAST MEDIUM; FARGLITAZAR; FLUORINE 18; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST CANCER; CELL DIFFERENTIATION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG POTENCY; DRUG STABILITY; DRUG SYNTHESIS; FEMALE; FLUORINATION; ISOTOPE LABELING; LIPID METABOLISM; LIPOPHILICITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROADIPOCYTE; PRODUCTIVITY; RADIOCHEMISTRY; RADIOIODINATION; RAT; REACTION ANALYSIS; SUBSTITUTION REACTION; TISSUE SPECIFICITY; ULLMANN TYPE CONDENSATION; VASCULAR DISEASE;

ANIMALS; FEMALE; FLUORINE RADIOISOTOPES; ISOTOPE LABELING; LIGANDS; POSITRON-EMISSION TOMOGRAPHY; PPAR GAMMA; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 59649109169     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.11.002     Document Type: Article

References (31)

1. Greene M.E., Blumberg B., McBride O.W., et al. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 4 (1995) 281-299
2. Issemann I., and Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (1990) 645-650
3. Lemberger T., Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 12 (1996) 335-363
4. Willson T.M., Cobb J.E., Cowan D.J., et al. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the anti-hyperglycemic activity of thiazolidinediones. J Med Chem 39 (1996) 665-668
5. Kliewer S.A., Lenhard J.M., Willson T.M., et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83 (1995) 813-819
6. Mueller E., Smith M., Sarraf P., et al. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc Natl Acad Sci U S A 97 (2000) 10990-10995
7. Burstein H.J., Demetri G.D., Mueller E., et al. Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a Phase II study. Breast Cancer Res Treat 79 (2003) 391-397
8. Panigrahy D., Shen L.Q., Kieran M.W., et al. Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs 12 (2003) 1925-1937
9. Demetri G.D., Fletcher C.D., Mueller E., et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A 96 (1999) 3951-3956
10. Mueller E., Sarraf P., Tontonoz P., et al. Terminal differentiation of human breast cancer through PPAR γ. Mol Cell 1 (1998) 465-470
11. Wang X., Southard R.C., and Kilgore M.W. The increased expression of peroxisome proliferator-activated receptor-γ1 in human breast cancer is mediated by selective promoter usage. Cancer Res 64 (2004) 5592-5596
12. Berger J.P., Akiyama T.E., and Meinke P.T. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26 (2005) 244-251
13. Kim S.-H., Jonson S.D., Welch M.J., et al. Fluorine-substituted ligands for the peroxisome proliferator-activated receptor gamma (PPARγ): potential imaging agents for metastatic tumors. Bioconjug Chem 12 (2001) 439-450
14. Lowell B.B., and Spiegelman B.M. Towards a molecular understanding of adaptive thermogenesis. Nature 404 (2000) 652-660
15. Bookout A.L., Jeong Y., Downes M., et al. Nuc recep signal atlas (2005). www.nursa.org/10.1621/datasets.02001
16. Cobb J.E., Blanchard S.G., Boswell E.G., et al. N-(2-Benzoylphenyl)-l-tyrosine PPARgamma agonists: 3. Structure-activity relationship and optimization of the N-aryl substituent. J Med Chem 41 (1998) 5055-5069
17. Collins J.L., Blanchard S.G., Boswell G.E., et al. N-(2-Benzoylphenyl)-l-tyrosine PPARγ agonists: 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety. J Med Chem 41 (1998) 5037-5054
18. Henke B.R., Blanchard S.G., Brackeen M.F., et al. N-(2-Benzoylphenyl)-l-tyrosine PPARγ agonists: 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem 41 (1998) 5020-5036
19. Willson T.M., Brown P.J., Sternbach D.D., et al. The PPARs: from orphan receptors to drug discovery. J Med Chem 43 (2000) 527-550
20. Mathews W.B., Foss C.A., Stoermer D., et al. Synthesis and biodistribution of (11)C-GW7845, a positron-emitting agonist for peroxisome proliferator-activated receptor-{gamma}. J Nucl Med 46 (2005) 1719-1726
21. Young P.W., Buckle D.R., Cantello B.C.C., et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ. J Pharmacol Exp Ther 284 (1998) 751-759
22. Lee B.C., Lee K.C., Lee H., et al. Strategies for the labeling of halogen-substituted peroxisome proliferator-activated receptor gamma ligands: potential positron emission tomography and single photon emission computed tomography imaging agents. Bioconjug Chem 18 (2007) 514-523
23. Lee B.C., Lee K.C., Lee H., et al. Synthesis and binding affinity of a fluorine-substituted peroxisome proliferator-activated gamma (PPARgamma) ligand as a potential positron emission tomography (PET) imaging agent. Bioconjug Chem 18 (2007) 507-513
24. Koser G.F., Wettach R.H., and Smith C.S. New methodology in iodonium salt synthesis. Reactions of [hydroxy(tosyloxy)iodo]arenes with aryltrimethylsilanes. J Org Chem 45 (1980) 1543-1544
25. Pike V.W., Butt F., Shah A., et al. Facile synthesis of substituted diaryliodonium tosylates by treatment of aryltributylstannanes with Koser's reagent. J Chem Soc Perkin Trans 1 (1999) 245-248
26. 18F]fluoride ion with diaryliodonium salts. J Chem Soc Perkin Trans 1 (1998) 2043-2046
27. Van der Puy M. Conversion of diaryliodonium salts to aryl fluorides. J Fluorine Chem 21 (1982) 385-392
28. Clement J.-B., Hayes J.F., Sheldrake H.M., et al. Synthesis of SB-214857 using copper catalyzed amination of aryl bromides with l-aspartic acid. Synlett (2001) 1423-1427
29. Ma D., Zhang Y., Yao J., et al. Accelerating effect induced by the structure of α-amino acid in the copper-catalyzed coupling reaction of aryl halides with α-amino acids. Synthesis of benzolactam-V8. J Am Chem Soc 120 (1998) 12459-12467
30. Xu L.-W., Xia C.G., Li J.W., et al. Efficient palladium/copper-cocatalyzed C-N coupling reaction of unactivated aryl bromide or iodide with amino acid under microwave heating. Catal Commun 5 (2004) 121-123
31. Sharp T.L., Dence C.S., Engelbach J.A., et al. Techniques necessary for multiple tracer quantitative small-animal imaging studies. Nucl Med Biol 32 (2005) 875-884